PT  - JOURNAL ARTICLE
AU  - Tiedemann, Lena J.
AU  - Meyhöfer, Sebastian M.
AU  - Francke, Paul
AU  - Beck, Judith
AU  - Büchel, Christian
AU  - Brassen, Stefanie
TI  - Insulin sensitivity in mesolimbic pathways predicts and improves with weight loss in older dieters
AID  - 10.1101/2022.03.21.22272418
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.21.22272418
4099  - http://medrxiv.org/content/early/2022/03/22/2022.03.21.22272418.short
4100  - http://medrxiv.org/content/early/2022/03/22/2022.03.21.22272418.full
AB  - Central insulin is critically involved in the regulation of hedonic feeding. Insulin resistance in overweight has recently been shown to reduce the inhibitory function of insulin in the human brain, but how this relates to effective weight management is unclear, especially in the elderly, who are highly vulnerable to hyperinsulinemia and in whom neural target systems of insulin action undergo age-related changes. Here, fifty overweight, pre-diabetic elderly participated in a double-blind, placebo-controlled pharmacological longitudinal fMRI study before and after randomization to a 3-month caloric restriction or active waiting group. Our data show that treatment outcome in dieters can be predicted by baseline measures of individual intranasal insulin (INI) inhibition of value signals in the ventral tegmental area related to sweet food liking as well as, independently, by peripheral insulin sensitivity. At follow-up, both INI inhibition of hedonic value signals in the nucleus accumbens and whole-body insulin sensitivity improved with weight loss. These data highlight the critical role of central insulin function in mesolimbic systems for weight management in humans and directly demonstrate that neural insulin function can be improved by weight loss even in older age, which may be essential for preventing metabolic disorders in later life.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00028576Funding StatementThis study was funded by the Deutsche Forschungsgemeinschaft (DFG, German Resarch Foundation).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the local ethics committee of the Ethical Board, Hamburg, Germany (Ethikkommission der Aerztekammer Hamburg; ID:PV4463, date: 14/10/2013)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data included in the reported results, tables and figures of the manuscript will be available online immediately after publication